Hemoglobin (Hb) A 2 ' is a hematologically silent variant of HbA 2 that is detected easily by highperformance liquid chromatography (HPLC), where it elutes in the S window. Our purposes were to define diagnostic criteria for the
Hemoglobin (Hb) A 2 ' (also called HbB2) is a hematologically silent variant of HbA 2 that results from the substitution of arginine for glycine at the 16th amino acid position of the δ-globin chain. [1] [2] [3] [4] [5] [6] [7] HbA 2 ' is the most common of the known HbA 2 variants and has been reported to occur in 1% to 2% of African Americans. 4 HbA 2 ' has been detected in heterozygous and homozygous states and in combination with other Hb variants and thalassemia. 5, [8] [9] [10] The major clinical significance of HbA 2 ' is that failure to detect it might lead to underestimation of the total HbA 2 and failure to recognize β-thalassemia minor. For the diagnosis or exclusion of β-thalassemia minor, the sum of the HbA 2 and the HbA 2 ' levels must be considered. 4 The substitution of arginine for glycine confers a net positive charge gain on the δ-globin chain, which accounts for its mobility cathodal to HbA 2 on alkaline electrophoresis. Because HbA 2 ' accounts for such a small percentage of the total Hb in heterozygotes, it is difficult to detect by this method. HbA 2 ' is easier to detect by isoelectric focusing (IEF); however, this method is not widely used as a primary screening method beyond the neonatal period, when HbA 2 levels normally are low. HbA 2 ' coelutes with HbA 2 by microcolumn chromatography, and, thus, the total HbA 2 level measured by this method would be expected to be accurate, although the HbA 2 ' component would not be identified. In recent years, high-performance liquid chromatography (HPLC) has replaced alkaline electrophoresis as the primary screening method for hemoglobinopathies in many laboratories. 11 HPLC offers the advantages of decreased manual labor, lower cost, and direct quantification of even minor Hb components, including HbA 2 . HbA 2 ' is perhaps detected most easily by HPLC, in which it produces a minor peak in the S window. 4, 12 In 2001, the University Hospitals of Cleveland Core Laboratory, Cleveland, OH, switched from alkaline electrophoresis to HPLC as the primary screening method for hemoglobin identification. Shortly afterward, we observed that some samples had small, unexplained peaks in the S window. We suspected that these cases might represent HbA 2 ', which prompted us to review all of our HPLC tracings retrospectively and prospectively to determine the prevalence of HbA 2 ' in our patient population and to better define the diagnostic criteria for HbA 2 '.
Materials and Methods
The study was approved by the institutional review board of University Hospitals of Cleveland. All HPLC tracings from November 1, 2001 , to December 31, 2003, were reviewed, and all new hemoglobinopathy and thalassemia diagnoses were identified. Samples with a peak in the S window accounting for less than 3% of the total Hb were selected for further examination as possible cases of HbA 2 ', after excluding samples with known HbS, HbC, or HbG-Philadelphia.
HPLC was performed on the Variant II (Bio-Rad, Hercules, CA) using the Beta-Thal Short Program (Bio-Rad). Briefly, EDTA-anticoagulated blood samples undergo hemolysis and dilution in the Variant II and then are injected into an assay-specific analytic cartridge, to which a buffer gradient of increasing ionic strength is delivered. Hb fractions are eluted from the cartridge based on their ionic interaction with the cartridge material. The separated Hb fractions pass through a flow cell, where absorbance is measured at 415 nm. A report is produced that includes a chromatogram and a relative quantification of each hemoglobin component. To aid in the interpretation of results, "windows" (ie, time ranges) have been established for the most frequently occurring Hb types based on their characteristic retention times. The manufacturer defines the HbA 2 window as 3.3 to 3.9 minutes and the HbS window as 4.3 to 4.7 minutes. The reference range for the proportion of HbA 2 by HPLC in our laboratory is 2.0% to 3.5% of the total Hb.
All patient samples with newly detected Hb variants by HPLC were submitted for confirmatory alkaline electrophoresis at pH 9.2. Alkaline electrophoresis was not done for all cases of HbA 2 ' because many of these cases were identified only retrospectively. Among prospectively identified suspected cases of HbA 2 ', representative samples were submitted for alkaline electrophoresis, and 4 samples were sent to Mayo Medical Laboratories, Rochester, MN, for verification or exclusion of HbA 2 ' by IEF. CBC count results were obtained for patients with HbA 2 ' if they were available in the laboratory information system.
Results
A total of 5,862 HPLC Hb screens were reviewed, and 1,350 new hemoglobinopathy diagnoses were made during this 26-month period. We identified 57 cases of the HbA 2 ' trait, making it the fourth most common hemoglobinopathy condition diagnosed in our patient population after HbS trait (n = 587), β-thalassemia minor (n = 183), and HbC trait (n = 163) ❚Figure 1❚. All patients with HbA 2 ' for whom race data were available were African American (42/42), and most were female (54/57). Many samples with HbA 2 ' were from women of childbearing age, which reflects the local practice of screening all new pregnant mothers for hemoglobinopathies.
The HbA 2 ' trait was considered present when the HPLC results showed a minor peak in the S window, there was no known history of HbS, and other interfering Hb variants could be excluded. For heterozygotes with the HbA 2 ' trait, the HbA 2 levels ranged from 1.2% to 2.0% (mean, 1.7%; SD, 0.17%), and the HbA 2 ' levels ranged from 1.0% to 2.0% (mean, 1.3%; SD, 0.18%). In 55 of 57 cases, the proportion of HbA 2 ' was slightly less than the proportion of HbA 2 . The retention times for HbA 2 ' ranged from 4.55 to 4.62 minutes (mean, 4.59 minutes; SD, 0.02 minute). These results are summarized in ❚Table 1❚. A representative chromatogram of the HbA 2 ' trait is shown in ❚Figure 2A❚. HbA 2 ' was confirmed in 3 representative cases by IEF. We were unable to detect HbA 2 ' by alkaline electrophoresis in any of our patient samples on which it was attempted. No cases of homozygous HbA 2 ' were identified during this period. CBC count results were available for 20 patients with the HbA 2 ' trait diagnosed after January 1, 2003. Of these patients, 14 had microcytosis, anemia, or both. Iron studies were not done, or results were not available for these patients. We identified 6 cases with possible double heterozygosity for HbA 2 ' and β-thalassemia minor based on HPLC findings. Cases were considered suggestive of HbA 2 '/β-thalassemia when the sum of HbA 2 and HbA 2 ' was greater than 4.0% of the total Hb. Ethnicity information was available for 4 of these cases, and all were African American. The clinical and hematologic data for these patients are shown in ❚Table 2❚. Three of these patients had low or borderline low mean cell volume. Two patients (cases 2 and 6) had normal mean cell volumes and low RBC counts. One of these patients (case 6) was a 49-year-old man with a myelodysplastic syndrome, hepatitis C, and hemochromatosis. Patient 2 was evaluated during pregnancy, but no other clinical information was available. No CBC results were available for case 4.
Three of the patients with possible HbA 2 '/β-thalassemia had HbA 2 ' levels that were equivalent to the levels seen in cases of simple HbA 2 ' trait, and the other 3 cases had HbA 2 ' levels exceeding 2% of total Hb. In all 6 cases, the HbA 2 levels were within the normal range. A representative chromatogram is shown in ❚Figure 2B❚.
There were 3 cases in which small peaks appeared in the S window and accounted for 0.6% to 0.8% of the total Hb. HbA 2 ' trait was considered unlikely in these cases because of the low percentage of Hb in the S window, the normal HbA 2 levels, and race other than African American in 2 of the 3 cases. One of these samples was submitted for IEF, which confirmed the absence of HbA 2 '. The explanation for these minor S window peaks remains unknown.
Discussion
Based on this large series of patients, the following criteria for the diagnosis of HbA 2 ' trait by HPLC are proposed: (1) S window peak of 1.0% to 2.0% of the total Hb, (2) HbA 2 level of 1.0% to 2.0% of the total Hb, (3) no previous diagnosis of HbS, and (4) absence of HbC and HbG. HbA 2 ' was the fourth most common Hb variant detected in our patient population, with an estimated prevalence of 1.1%. Our HPLC findings and prevalence estimates concur with the results of Joutovsky et al, 12 who analyzed more than 60,000 samples in an ethnically diverse patient population. However, the actual prevalence of HbA 2 ' in both patient populations probably is higher because double heterozygosity for HbA 2 ' and HbS or HbC cannot be detected by the current Variant II method. In addition, a selection bias favoring pregnant females and patients undergoing evaluation for anemia skewed our population sample, such that hematologically normal males and nonpregnant females are underrepresented. In our series, HbA 2 ' was not detected in any persons who were not African diagnosis by alternative methods is recommended, as clinically indicated. We also noted that 3 patients had HbA 2 ' levels ranging from 1.0% to 1.5%, and 3 patients had higher HbA 2 ' levels, ranging from 2.1% to 2.3%. Previous family studies of persons with double heterozygosity for these 2 conditions have suggested that the proportion of HbA 2 ' might be determined by whether the δ-chain mutation is in the cis-or trans-configuration with the β-thalassemia mutation. 5, 7, 9, 10 Several hemoglobinopathy conditions that might interfere with the detection and diagnosis of HbA 2 ' are listed in ❚Table 3❚. In the HbS trait and HbSS conditions, HbA 2 ' will be masked by the overwhelming amount of HbS in the S window. In HbC trait and HbCC conditions, the glycosylated fraction of HbC elutes in the S window and also will mask the presence of HbA 2 ' ❚Figure 3A❚. In our patient population, HbS and American, which is consistent with the published literature on ethnic distribution of HbA 2 '. However, it is reasonable to expect that HbA 2 ' will occur in persons of mixed racial background, and, therefore, race other than African American should not exclude the diagnosis if all other diagnostic criteria are met.
HbA 2 ' is a hematologically silent Hb variant; however, many of our patients were anemic, microcytic, or both. Iron deficiency might explain the anemia and microcytosis in some of these patients, and if so, this might have biased the mean HbA 2 and mean HbA 2 ' levels obtained in our series, because iron deficiency causes decreased HbA 2 production. This effect seems unlikely, however, because the mean HbA 2 ' level of 1.3% in our 57 patients is similar to the mean of 1.2% obtained by Joutovsky et al 12 in 81 cases of HbA 2 ' trait.
The recognition of HbA 2 ' is important for the diagnosis and exclusion of β-thalassemia minor. In fact, 5 of 6 cases of suspected HbA 2 '/β-thalassemia were missed on initial evaluation and were identified during retrospective review. We were unable to obtain fresh samples to submit for confirmatory testing in any of these cases. Although the RBC indices in some of these cases were not consistent with β-thalassemia minor, coexisting hematologic disorders (such as myelodysplastic syndrome and liver disease in case 6) might account for the observed values. When HPLC results suggest HbA 2 '/β-thalassemia and RBC indices are inconsistent with this interpretation, confirmation of the HbC are the most common β-chain Hb variants detected, and, therefore, the prevalence of HbA 2 ' in our patient population probably is underestimated. On the other hand, some hemoglobinopathy conditions produce HPLC results that could be misinterpreted as HbA 2 '. Patients with HbSS who have undergone exchange transfusion might have extremely low levels of residual HbS. We have observed HbS levels as low as 2.6% in such cases ❚Figure 3B❚. If the laboratory is unaware of the history of sickle cell anemia and exchange transfusion, the HPLC results could be misinterpreted as HbA 2 '. Another possibility is that a patient who has received a transfusion from a donor with HbS trait also could have a very low level of HbS. HbG-Philadelphia, which is an α-chain variant, elutes in the D window, and the HbG 2 component, which consists of normal δ-chains combined with αG chains, also elutes in the S window and could be confused with HbA 2 ' ❚Figure 3C❚. Hb Manitoba and Hb Montgomery have retention times identical to HbA 2 ' but account for a significantly greater proportion of the total Hb and, therefore, should not be confused with HbA 2 '. 12 HbA 2 ' is a δ-chain variant readily detectable by HPLC. As HPLC becomes more widely used for hemoglobinopathy screening, familiarity with the diagnostic criteria for HbA 2 ' will lead to more frequent recognition of this clinically harmless Hb variant.
